Loading clinical trials...
Loading clinical trials...
Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies
Conditions
Interventions
4SCAR19 and 4SCAR22
4SCAR19 and 4SCAR38
+4 more
Locations
4
China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China
Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center
Kunming, Yunnan, China
Start Date
August 1, 2025
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2029
Last Updated
September 8, 2025
NCT07349849
NCT06590961
NCT05780034
NCT03050190
NCT06351527
NCT06958679
Lead Sponsor
Shenzhen Geno-Immune Medical Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions